ProPhase Labs, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ProPhase Labs, Inc. (PRPH) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $12.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2026-08-19
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2026-03-31 was $12.00K, a 77.36% decline year-over-year.
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2025-12-31 was $0.00.
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2025 was $120.00K, a 95.55% decline from fiscal 2024.
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2024 was $2.70M.
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2023 was -$298.00K.
- ProPhase Labs, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$306.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $12.00K 10-Q · filed 2026-08-19 | $12.00K derived: sum of 3 quarters · filed 2026-08-19 | $12.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | $12.00K 10-Q/A · filed 2026-07-09 | $12.00K derived: sum of 2 quarters · filed 2026-07-09 | $12.00K derived: sum of 3 quarters · filed 2026-07-09 | $79.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $67.00K derived: sum of 3 quarters · filed 2026-08-19 | $120.00K 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $67.00K derived: sum of 2 quarters · filed 2026-08-19 | $120.00K 10-Q · filed 2025-11-19 | $80.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $67.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $120.00K 10-Q · filed 2026-08-19 | $80.00K derived: sum of 3 quarters · filed 2026-08-19 | $160.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $53.00K 10-Q/A · filed 2026-07-09 | $13.00K derived: sum of 2 quarters · filed 2026-07-09 | $93.00K derived: sum of 3 quarters · filed 2026-07-09 | $243.00K derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | -$40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $40.00K derived: sum of 2 quarters · filed 2026-06-01 | $190.00K derived: sum of 3 quarters · filed 2026-06-01 | $2.70M 10-K · filed 2026-06-01 |
| 2024-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $230.00K derived: sum of 2 quarters · filed 2025-11-19 | $2.74M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $150.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.66M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $2.51M 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | -$298.00K 10-K · filed 2025-04-01 | |||
| 2015-03-31 | -$37.00K 10-Q · filed 2015-05-13 | -$227.00K derived: sum of 2 quarters · filed 2015-05-13 | -$265.00K derived: sum of 3 quarters · filed 2015-05-13 | -$326.00K derived: sum of 4 quarters · filed 2015-05-13 |
| 2014-12-31 | -$190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | -$228.00K derived: sum of 2 quarters · filed 2015-03-27 | -$289.00K derived: sum of 3 quarters · filed 2015-03-27 | -$306.00K 10-K · filed 2015-03-27 |
| 2014-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$99.00K derived: sum of 2 quarters · filed 2014-11-13 | -$116.00K 10-Q · filed 2014-11-13 | -$234.00K derived: sum of 4 quarters · filed 2015-05-13 |
| 2014-06-30 | -$61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | -$78.00K 10-Q · filed 2014-08-12 | -$196.00K derived: sum of 3 quarters · filed 2015-05-13 | -$270.00K derived: sum of 4 quarters · filed 2015-05-13 |
| 2014-03-31 | -$17.00K 10-Q · filed 2015-05-13 | -$135.00K derived: sum of 2 quarters · filed 2015-05-13 | -$209.00K derived: sum of 3 quarters · filed 2015-05-13 | -$451.00K derived: sum of 4 quarters · filed 2015-05-13 |
| 2013-12-31 | -$118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | -$192.00K derived: sum of 2 quarters · filed 2015-03-27 | -$434.00K derived: sum of 3 quarters · filed 2015-03-27 | -$442.00K 10-K · filed 2015-03-27 |
| 2013-09-30 | -$74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$316.00K derived: sum of 2 quarters · filed 2014-11-13 | -$324.00K 10-Q · filed 2014-11-13 | |
| 2013-06-30 | -$242.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | -$250.00K 10-Q · filed 2014-08-12 | ||
| 2013-03-31 | -$8.00K 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | -$310.00K 10-K · filed 2015-03-27 | |||
| 2011-12-31 | -$134.00K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |